首页/数据集/Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in Adults

Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in Adults

NCATS Open Data2022-11-08 更新2026-08-08 收录

新冠疫苗I期临床试验

疫苗免疫原性

数据链接：

https://doi.org/10.1101/2022.10.18.22281050 数据链接链接失效反馈

官方服务：

资源简介：

Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in Adults

应用场景：

创建时间：

2022-10-19

疫苗免疫原性

中和抗体动态监测

Female BALB/c mice (4–6 weeks old) were i.p. inoculated with three EV71 FCP-As (V1, V2, and V3) containing 200 U antigen. The sera were isolated and tested at 7, 14, 21, 28, 56 and 84 d post-inoculati

NIAID Data Ecosystem100

Evaluation of the effectiveness and immunogenicity of quadrivalent HPV vaccination over 10 years

HPV疫苗

疫苗免疫原性

Objective To assess the effectiveness and long-term immunogenicity of the quadrivalent human papillomavirus vaccine (4v HPV vaccine) in Chinese women aged 20-45 at ten years after vaccination.Methods

DataCite Commons2025-04-27 更新50

Dataset from Phase IV Open Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.

疫苗免疫原性

疫苗安全性监测

To evaluate the safety and immunogenicity of GSK Biologicals' live attenuated MMR vaccine (Priorix) in a local population in Singapore. The vaccine was administered as a single dose to healthy childre

NIAID Data Ecosystem10

Antibody responses according to vaccine groups.

疫苗免疫原性

孕妇免疫反应

P: Pregnant. NP: Non-pregnant. GMT: Geometric mean titer. GMR: Geometric mean ratio. CI: Confidence interval. Sero-protection: Titer ≥40. Sero-conversion: Pre titer<10, Post titer ≥40. Significant inc

NIAID Data Ecosystem70

疫苗免疫原性

免疫应答

aGroups of 5 WT or IL-23 KO mice (p19M KO and p19G KO) were infected with 105 LVS ID and sera collected at Day 42, or were anesthetized and infected with 2×103 LVS IN and sera collected at day 35. Ser

Figshare2015-12-02 更新40

Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in Adults

资源简介：

相关数据集